Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05798819 is registered in ClinicalTrials.gov with Guangzhou Gloria Biosciences Co., Ltd. as lead sponsor.

NCT NCT05798819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
April 20, 2023
Completion date
December 1, 2030
Enrollment
424 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

persistent, recurrent, or metastatic cervical cancer